Taking everything into account, SNY scores 5 out of 10 in our fundamental rating. SNY was compared to 191 industry peers in the Pharmaceuticals industry. While SNY has a great profitability rating, there are quite some concerns on its financial health. SNY has a correct valuation and a medium growth rate. Finally SNY also has an excellent dividend rating.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.63% | ||
| ROE | 18.84% | ||
| ROIC | 13.35% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.61% | ||
| PM (TTM) | 20.63% | ||
| GM | 72.29% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.3 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.29 | ||
| Fwd PE | 9.51 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.03% |
47.83
+0.34 (+0.72%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.03% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.29 | ||
| Fwd PE | 9.51 | ||
| P/S | 1.46 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.34 | ||
| P/tB | 22.27 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.63% | ||
| ROE | 18.84% | ||
| ROCE | 16.17% | ||
| ROIC | 13.35% | ||
| ROICexc | 14.69% | ||
| ROICexgc | 65.49% | ||
| OM | 23.61% | ||
| PM (TTM) | 20.63% | ||
| GM | 72.29% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.3 | ||
| Altman-Z | N/A |
ChartMill assigns a fundamental rating of 5 / 10 to SNY.
ChartMill assigns a valuation rating of 6 / 10 to SANOFI-ADR (SNY). This can be considered as Fairly Valued.
SANOFI-ADR (SNY) has a profitability rating of 8 / 10.
The Price/Earnings (PE) ratio for SANOFI-ADR (SNY) is 10.29 and the Price/Book (PB) ratio is 1.34.
The dividend rating of SANOFI-ADR (SNY) is 8 / 10 and the dividend payout ratio is 34.36%.